Sage Therapeutics To Present At American Epilepsy Society 70th Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations at the American Epilepsy Society (AES) 70 th Annual Meeting, taking place December 2-6, 2016 in Houston, TX. Members of the company's medical affairs team will be accessible at booth number 918.

Below is the schedule for the presentations and a Sage-sponsored scientific exhibit:

Date: Saturday, December 3, 2016 Poster Presentation Time: 12:00 p.m. - 6:00 p.m. CT Location: Hall A3/Level 3, George R. Brown Convention Center Poster Number: 1.261 Title: SAGE-217, a next generation neuroactive steroid positive allosteric modulator of synaptic and extra-synaptic GABA A receptors, is active against audiogenic seizures in Fmr1 knockout mice

Date: Sunday, December 4, 2016 Poster Presentation Time: 10:00 a.m. - 4:00 p.m. CT Location: Hall A3/Level 3, George R. Brown Convention Center Poster Number: 2.187 Title: SGE-516, a next generation neuroactive steroid, reduces status epilepticus (SE) after a 20 or 40-minute treatment delay in a rat model of soman intoxication

Date: Sunday, December 4, 2016 Poster Presentation Time: 10:00 a.m. - 4:00 p.m. CT Location: Hall A3/Level 3, George R. Brown Convention Center Poster Number: 2.185 Title: SAGE-689, a potent and selective next generation neuroactive steroid, reduces electrographic seizure activity in a rat model of pharmacoresistant status epilepticus while phenytoin does not

Date: Sunday, December 4, 2016 Sage Sponsored Scientific Exhibit Time: 2 p.m. - 5 p.m. CT Location: Room 360 AD Title: Neuroactive Steroids in the Treatment of GABA A-Related Disorders.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit  www.sagerx.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161201006314/en/

Copyright Business Wire 2010

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX